Well it's important, because the particular new lead for drug targeting is not super valuable, they are a dime a dozen, easier to find than a startup idea. Actually driving a successful drug development program is an entirely different matter that can only be established with $10-$100M of early exploration, with a successful drug costing much more to get to market.

It could also be that particular prioritization method that uses Gemma is useful in its own, but we won't know that unless it is somehow benchmarked against the many alternatives that have been used up until now. And in other benchmark settings, these cell sentence methods have not been that impressive.